WESTFORD, Mass., Nov. 6, 2013 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that Australia’s Therapeutic Goods Administration has granted marketing clearance for the PicoSure Picosecond Laser, the world’s first picosecond laser for the removal of tattoos and benign pigmented lesions. PicoSure was introduced in the United States earlier this year after receiving clearance from the U.S. Food and Drug Administration. The product also is being marketed in the European Union and Canada.
“PicoSure continues to be enthusiastically received by physicians and consumers in North America and Europe, and we are excited about the opportunity to market the product to our customers and their patients in Australia, which is a new direct sales territory for the Company,” said Cynosure President and CEO Michael Davin.
The Company also received approval from the China Food and Drug Administration to market Smartlipo MPX LaserBodySculpting Workstation, the industry’s leading laser-assisted lipolysis system designed to disrupt fat cells and tighten tissue through tissue coagulation. In addition, the PinPointe FootLaser, which Cynosure distributes through an exclusive worldwide agreement with NuvoLase Inc., has been cleared by the Korea Food & Drug Administration for the treatment of Onychomycosis, commonly known as nail fungus.
“Further expanding our international product reach is an important part of our long-term growth strategy,” Davin said. “International markets generate nearly half of our total laser revenue. Our goal is to continue to enhance our presence in high-growth regions by capitalizing on our outstanding brand reputation, broad distribution capabilities and strong customer relationships. With our innovative laser treatments rapidly gaining in popularity and accessibility around the world, Cynosure is playing an integral role in driving the growth of the global aesthetic market.”
About Cynosure, Inc.
Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure’s product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 100 other countries. For corporate or product information, visit Cynosure’s website at www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market acceptance of PicoSure in Australia, market acceptance of Smartlipo MPX in China, market acceptance of the PinPointe FootLaser in Korea, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions and other factors discussed in Cynosure’s most recent Annual Report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure’s views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure’s views as of any date subsequent to the date of this press release.
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
SOURCE Cynosure
Help employers find you! Check out all the jobs and post your resume.
